153 related articles for article (PubMed ID: 12424552)
1. SR146131, a cholecystokinin-A receptor agonist, antagonizes prepulse inhibition deficits produced by dizocilpine and DOI.
Shilling PD; Feifel D
Psychopharmacology (Berl); 2002 Nov; 164(3):285-93. PubMed ID: 12424552
[TBL] [Abstract][Full Text] [Related]
2. Clozapine enhances disruption of prepulse inhibition after sub-chronic dizocilpine- or phencyclidine-treatment in Wistar rats.
Schwabe K; Brosda J; Wegener N; Koch M
Pharmacol Biochem Behav; 2005 Feb; 80(2):213-9. PubMed ID: 15680174
[TBL] [Abstract][Full Text] [Related]
3. Iloperidone reduces sensorimotor gating deficits in pharmacological models, but not a developmental model, of disrupted prepulse inhibition in rats.
Barr AM; Powell SB; Markou A; Geyer MA
Neuropharmacology; 2006 Sep; 51(3):457-65. PubMed ID: 16762376
[TBL] [Abstract][Full Text] [Related]
4. WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A novel 5-hydroxytryptamine 2C receptor-selective agonist with preclinical antipsychotic-like activity.
Marquis KL; Sabb AL; Logue SF; Brennan JA; Piesla MJ; Comery TA; Grauer SM; Ashby CR; Nguyen HQ; Dawson LA; Barrett JE; Stack G; Meltzer HY; Harrison BL; Rosenzweig-Lipson S
J Pharmacol Exp Ther; 2007 Jan; 320(1):486-96. PubMed ID: 17038512
[TBL] [Abstract][Full Text] [Related]
5. Combined alpha 2-adrenergic/D2 dopamine receptor blockade fails to reproduce the ability of clozapine to reverse phencyclidine-induced deficits in prepulse inhibition of startle.
Ballmaier M; Zoli M; Mazzoncini R; Gennarelli M; Spano F
Psychopharmacology (Berl); 2001 Dec; 159(1):105-10. PubMed ID: 11797077
[TBL] [Abstract][Full Text] [Related]
6. Phencyclidine-induced deficits in prepulse inhibition of startle are blocked by prazosin, an alpha-1 noradrenergic antagonist.
Bakshi VP; Geyer MA
J Pharmacol Exp Ther; 1997 Nov; 283(2):666-74. PubMed ID: 9353384
[TBL] [Abstract][Full Text] [Related]
7. Effects of antipsychotics and selective D3 antagonists on PPI deficits induced by PD 128907 and apomorphine.
Zhang M; Ballard ME; Unger LV; Haupt A; Gross G; Decker MW; Drescher KU; Rueter LE
Behav Brain Res; 2007 Aug; 182(1):1-11. PubMed ID: 17570538
[TBL] [Abstract][Full Text] [Related]
8. Clozapine antagonizes phencyclidine-induced deficits in sensorimotor gating of the startle response.
Bakshi VP; Swerdlow NR; Geyer MA
J Pharmacol Exp Ther; 1994 Nov; 271(2):787-94. PubMed ID: 7965797
[TBL] [Abstract][Full Text] [Related]
9. Novel antipsychotic-like effects on prepulse inhibition of startle produced by a neurotensin agonist.
Feifel D; Reza TL; Wustrow DJ; Davis MD
J Pharmacol Exp Ther; 1999 Feb; 288(2):710-3. PubMed ID: 9918579
[TBL] [Abstract][Full Text] [Related]
10. The muscarinic receptor agonist xanomeline has an antipsychotic-like profile in the rat.
Stanhope KJ; Mirza NR; Bickerdike MJ; Bright JL; Harrington NR; Hesselink MB; Kennett GA; Lightowler S; Sheardown MJ; Syed R; Upton RL; Wadsworth G; Weiss SM; Wyatt A
J Pharmacol Exp Ther; 2001 Nov; 299(2):782-92. PubMed ID: 11602695
[TBL] [Abstract][Full Text] [Related]
11. Nicotine and clozapine actions on pre-pulse inhibition deficits caused by N-methyl-D-aspartate (NMDA) glutamatergic receptor blockade.
Levin ED; Petro A; Caldwell DP
Prog Neuropsychopharmacol Biol Psychiatry; 2005 May; 29(4):581-6. PubMed ID: 15866361
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of the antidepressant mirtazapine on amphetamine- and dizocilpine-induced PPI deficits.
Larrauri JA; Levin ED
Pharmacol Biochem Behav; 2012 Jul; 102(1):82-7. PubMed ID: 22469866
[TBL] [Abstract][Full Text] [Related]
13. The neurotensin agonist NT69L improves sensorimotor gating deficits in rats induced by a glutamatergic antagonist, but not by dopaminergic agonists.
Secchi RL; Sung E; Hedley LR; Button D; Schreiber R
Behav Brain Res; 2009 Sep; 202(2):192-7. PubMed ID: 19463701
[TBL] [Abstract][Full Text] [Related]
14. Sensorimotor gating effects produced by repeated dopamine agonists in a paradigm favoring environmental conditioning.
Feifel D; Priebe K; Johnstone-Miller E; Morgan CJ
Psychopharmacology (Berl); 2002 Jul; 162(2):138-46. PubMed ID: 12110991
[TBL] [Abstract][Full Text] [Related]
15. SR146131: a new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. II. In vivo pharmacological characterization.
Bignon E; Alonso R; Arnone M; Boigegrain R; Brodin R; Gueudet C; Héaulme M; Keane P; Landi M; Molimard JC; Olliero D; Poncelet M; Seban E; Simiand J; Soubrié P; Pascal M; Maffrand JP; Le Fur G
J Pharmacol Exp Ther; 1999 May; 289(2):752-61. PubMed ID: 10215649
[TBL] [Abstract][Full Text] [Related]
16. Effects of the PCP analog dizocilpine on sensory gating: potential relevance to clinical subtypes of schizophrenia.
al-Amin HA; Schwarzkopf SB
Biol Psychiatry; 1996 Oct; 40(8):744-54. PubMed ID: 8894067
[TBL] [Abstract][Full Text] [Related]
17. Amphetamine-induced disruption of prepulse inhibition in mice with reduced NMDA receptor function.
Moy SS; Perez A; Koller BH; Duncan GE
Brain Res; 2006 May; 1089(1):186-94. PubMed ID: 16638606
[TBL] [Abstract][Full Text] [Related]
18. Effects of LU-111995 in three models of disrupted prepulse inhibition in rats.
Geyer MA; Swerdlow NR; Lehmann-Masten V; Teschendorf HJ; Traut M; Gross G
J Pharmacol Exp Ther; 1999 Aug; 290(2):716-24. PubMed ID: 10411583
[TBL] [Abstract][Full Text] [Related]
19. Antipsychotic potential of CCK-based treatments: an assessment using the prepulse inhibition model of psychosis.
Feifel D; Reza T; Robeck S
Neuropsychopharmacology; 1999 Feb; 20(2):141-9. PubMed ID: 9885794
[TBL] [Abstract][Full Text] [Related]
20. Disruption of prepulse inhibition and increases in locomotor activity by competitive N-methyl-D-aspartate receptor antagonists in rats.
Bakshi VP; Tricklebank M; Neijt HC; Lehmann-Masten V; Geyer MA
J Pharmacol Exp Ther; 1999 Feb; 288(2):643-52. PubMed ID: 9918570
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
